ESR1 and breast cancer: TSC showed stronger growth inhibition toward ERα positive breast cancer cell lines (IC50 is 0.5–1 mg/ml) than the other four ERα negative breast cell lines (IC50>1.5 mg/ml) (Fig. 1).